PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33177546-4	2020	Metformin alone slightly deteriorated the aspartate and alanine aminotransferase (AST/ALT) values, whereas co-treatment with GW7647 and metformin greatly suppressed liver injury and fibrosis via activation of the AMP-activated protein kinase (AMPK) pathway.	Metformin	0-9	glutamic pyruvic transaminase, soluble	Mus musculus	86-89	
33968030-3	2021	Using an adenovirus (Ad)-induced viral hepatitis mouse model, we found that metformin treatment significantly attenuated liver injury, with reduced serum aspartate transaminase (AST) and alanine transaminase (ALT) levels and liver histological changes, presumably via decreased effector T cell responses.	Metformin	76-85	glutamic pyruvic transaminase, soluble	Mus musculus	187-207	
33968030-3	2021	Using an adenovirus (Ad)-induced viral hepatitis mouse model, we found that metformin treatment significantly attenuated liver injury, with reduced serum aspartate transaminase (AST) and alanine transaminase (ALT) levels and liver histological changes, presumably via decreased effector T cell responses.	Metformin	76-85	glutamic pyruvic transaminase, soluble	Mus musculus	209-212	
33177546-4	2020	Metformin alone slightly deteriorated the aspartate and alanine aminotransferase (AST/ALT) values, whereas co-treatment with GW7647 and metformin greatly suppressed liver injury and fibrosis via activation of the AMP-activated protein kinase (AMPK) pathway.	Metformin	136-145	glutamic pyruvic transaminase, soluble	Mus musculus	86-89	
27562556-8	2016	Our data showed that pretreatment with metformin protected against APAP hepatotoxicity, as indicated by the over 80% reduction in plasma alanine aminotransferase (ALT) activities and significant decrease in centrilobular necrosis.	Metformin	39-48	glutamic pyruvic transaminase, soluble	Mus musculus	137-161	
27252117-12	2016	Metformin (200 mg/kg/d) significantly normalized MDA, SOD and GSH levels (p < 0.001), and exerted a hepatoprotective effect by significant decreasing ALT, AST and ALP concentrations (p < 0.001).	Metformin	0-9	glutamic pyruvic transaminase, soluble	Mus musculus	153-156	
28921708-4	2017	Both scopoletin and metformin lowered blood glucose and HbA1c , serum ALT, TNF-alpha and IL-6 levels, glucose intolerance, and hepatic lipid accumulation compared with the diabetic control group.	Metformin	20-29	glutamic pyruvic transaminase, soluble	Mus musculus	70-73	
27562556-8	2016	Our data showed that pretreatment with metformin protected against APAP hepatotoxicity, as indicated by the over 80% reduction in plasma alanine aminotransferase (ALT) activities and significant decrease in centrilobular necrosis.	Metformin	39-48	glutamic pyruvic transaminase, soluble	Mus musculus	163-166	
26265045-4	2015	The results indicated that treatment with metformin significantly suppressed the elevation of plasma alanine aminotransferase (ALT) and aspartate aminotransferase (AST), the activation of caspase cascade and the induction of cleaved caspase-3.	Metformin	42-51	glutamic pyruvic transaminase, soluble	Mus musculus	101-125	
26265045-4	2015	The results indicated that treatment with metformin significantly suppressed the elevation of plasma alanine aminotransferase (ALT) and aspartate aminotransferase (AST), the activation of caspase cascade and the induction of cleaved caspase-3.	Metformin	42-51	glutamic pyruvic transaminase, soluble	Mus musculus	127-130	
22330083-3	2012	We found that pretreatment with metformin significantly decreased serum ALT and AST levels in LPS/D-Gal-exposed mice.	Metformin	32-41	glutamic pyruvic transaminase, soluble	Mus musculus	72-75